GOSURANEMAB
Nonfluent Aphasia, Progressive
University of California, San Franciscomonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Nonfluent Aphasia, Progressive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLORTAUCIPIR Mayo Clinic | Phase 4 | BB |
LEVODOPA Shirley Ryan AbilityLab | Phase 2/3 | B |
carbidopa Shirley Ryan AbilityLab | Phase 2/3 | B |
Neflamapimod EIP Pharma Inc | Phase 2 | CCC |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
Aadvac1 Axon Neuroscience SE | Phase 1 | CC |
Same molecule, other indications
GOSURANEMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →